Rochester, MNNCT06349642Now EnrollingIRB Ready

Early Stage Triple-Negative Breast Carcinoma Clinical Trial in Rochester, MN

Access cutting-edge early stage triple-negative breast carcinoma treatment through this clinical trial at a research site in Rochester. Study-provided care at no cost to qualified participants.

Sponsored by Mayo Clinic

Quick Self-Assessment

See if you qualify for this Rochester location

Preparing your pre-screening questions…

Expert Care in Rochester

Access early stage triple-negative breast carcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related early stage triple-negative breast carcinoma treatment provided free

Apply for This Rochester Location

Check if you qualify for this early stage triple-negative breast carcinoma clinical trial in Rochester, MN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Rochester

    Convenient for MN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Rochester site if eligible
  4. 4Begin participation

About This Early Stage Triple-Negative Breast Carcinoma Study in Rochester

This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.

Sponsor: Mayo Clinic

Who Can Participate

Inclusion Criteria

Subjects must meet one of the following criteria:
Subjects suspected of or diagnosed with the following Stage IV/metastatic or recurrent malignancies:
Lung: Non-small Cell Lung Cancer (NSCLC)
Skin: Cutaneous Malignancy, excluding Uveal Melanoma
Esophageal Cancer
Cervical Cancer
Endometrial Cancer
Colon Cancer: Mismatch repair deficient (dMMR) CRC only
All solid tumors with high tumor mutation burden (TMB)
All solid tumors that are microsatellite instability high (MSI-H)
All mismatch repair deficient (dMMR) solid tumors
Liver Cancer
Any solid tumor with measurable disease that is eligible for pure ICI therapy or that the clinician plans to treat with immune checkpoint inhibitor (ICI) therapy. NOTE: This can be in the setting of a trial, compassionate use, or the use of appropriate laboratory developed tests (LDTs) that, per clinician, render the patient eligible for ICI therapy, either frontline or a later line. OR
Subjects suspected of or diagnosed with the following Stage III per provider discretion or IV/metastatic malignancies:
Kidney: Clear Cell Renal Cell Carcinoma (ccRCC)
Bladder: Urothelial Carcinoma (UC)
Any solid tumor with measurable disease that is eligible for pure ICI therapy or that the clinician plans to treat with ICI therapy. NOTE: This can be in the setting of a trial, compassionate use, or the use of appropriate LDT tests that per clinician, render the patient eligible for ICI therapy, either frontline or a later line OR
Patients who will be receiving neoadjuvant CPI for the following resectable early-stage malignancies:
Breast Cancer: Triple negative breast cancer (TNBC)
Lung: Non-small cell lung cancer (NSCLC)
NOTE: Patients with suspected NSCLC who would be eligible for neoadjuvant checkpoint inhibitor (CPI) are eligible to enroll per provider discretion
Any solid tumor that is eligible for pure ICI therapy or that the clinician plans to treat with ICI therapy. NOTE: This can be in the setting of a trial, compassionate use, or the use of appropriate LDT tests that per clinician, render the patient eligible for ICI therapy, either frontline or a later line
LOCALLY ADVANCED/METASTATIC PATIENTS: Measurable disease as defined per protocol NOTE: Tumor lesions in a previously irradiated area are not considered measurable disease; Disease that is measurable by physical examination only is not eligible.
NEOADJUVANT PATIENTS: Subjects must be eligible based on investigator discretion to receive approved CPI therapy.
Subjects who are newly diagnosed or have suspected cancer must be treatment-naïve at the time of biopsy.
Subjects who are Stage I, II, or III and have progressed to metastatic cannot have received any anti-cancer treatment for at least 2 - 4 weeks (depending upon the washout period of prior anti-cancer treatment) prior to biopsy as per the agents used.
ECOG Performance Status (PS) 0, 1 or 2.
Negative pregnancy test done ≤7 days prior to enrollment, for persons of childbearing potential only
Female subjects must not be pregnant or breastfeeding and must use appropriate methods of contraception when applicable.
Subjects must be clinically able, at investigator discretion, and willing to undergo either:
additional biopsy passes during their standard of care biopsy, OR
a biopsy for research only, if applicable.
NOTE: These additional biopsies may either be collected from the primary tumor or a metastatic site amenable to biopsies per the clinician.
Subjects with a known secondary cancer diagnosis are eligible to participate if participation does not interfere with systemic anti-cancer standard of care treatment for suspected primary diagnosis.
Provide written informed consent

Exclusion Criteria

Pregnant women because this study involves a greater than minimal risk procedure (biopsy)
Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety for the biopsy
Immunocompromised patients and patients known to be HIV positive and currently receiving antiretroviral therapy
NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
Uncontrolled intercurrent illness including, but not limited to:
ongoing or active infection
psychiatric illness/social situations that would limit compliance with study requirements
Subjects who are enrolled or plan to be enrolled in a blinded cancer therapeutic treatment trial

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Rochester?

Yes, this clinical trial (NCT06349642) has an active research site in Rochester, MN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Early Stage Triple-Negative Breast Carcinoma Treatment Options in Rochester, MN

If you're searching for early stage triple-negative breast carcinoma treatment options in Rochester, MN, this clinical trial (NCT06349642) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Rochester research site is actively enrolling participants for this clinical trial. You'll receive care from experienced early stage triple-negative breast carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all early stage triple-negative breast carcinoma clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Rochester, MN

See all breast cancer clinical trials recruiting in Rochester — not just this study.

Browse Breast Cancer Trials in Rochester →

Browse More Trials by Condition

Breast Cancer TrialsTriple Negative Breast Cancer TrialsAnkylosing Spondylitis TrialsGeographic Atrophy TrialsAll Conditions →

Ready to Join in Rochester?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Rochester, MN